Angiotensin 1-7

DRUG6 trials

Conditions

COVID-19CoronavirusCoronavirus Sars-Associated as Cause of Disease Classified ElsewhereHIV InfectionsHeart Failure NYHA Class IIHeart Failure NYHA Class IIIHeart Failure NYHA Class IVHypertension

Early Phase 1

Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects

NCT03001271

Instituto de Cardiologia do Rio Grande do SulHypertension

Start: 2014-01-31End: 2017-03-31Target: 32Updated: 2016-12-23

Angiotensin-(1-7) in Peripheral Arterial Disease

TerminatedNCT03240068

Milton S. Hershey Medical CenterPeripheral Arterial Disease

Start: 2017-09-01End: 2020-03-09Updated: 2024-05-03

Phase 1

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

TerminatedNCT00757250

US Biotest, Inc.HIV Infections

Start: 2008-09-30End: 2011-12-31Updated: 2012-02-29

Biomarker Study: Heart Failure Patients at Risk

NCT05336175

University of ArizonaHeart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV

Start: 2022-04-30End: 2023-12-31Target: 40Updated: 2022-04-20

Phase 2

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

NCT04332666

Erasme University HospitalCoronavirus, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere, Respiratory Failure +1

Start: 2021-12-30End: 2023-06-15Target: 60Updated: 2021-08-02

Angiotensin 1-7 as a Therapy in the Treatment of COVID-19

NCT04605887

Rambam Health Care CampusCOVID-19

Start: 2021-01-18End: 2024-04-30Target: 120Updated: 2021-01-22

Angiotensin 1-7

Sponsors

Conditions

Early Phase 1

Phase 1

Phase 2